Loading
A phase 1 trial of ORM-1153 run by Orum Therapeutics USA, Inc., now recruiting.
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression is a phase 1 interventional study registered as NCT07809906 by Orum Therapeutics USA, Inc., with 42 participants planned, started 2026-09-23. Conditions recorded: CD123+ Acute Myeloid Leukemia. Interventions recorded: ORM-1153.
Shares Orum Therapeutics, Acute myeloid leukaemia and the tag pipeline.
Shares Orum Therapeutics and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/